RASA VAICENAS: Open Payments
NPI 1275211872 · CONNELLSVILLE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,857 in 95 payments from 13 companies in 2025. Trend: 2023 $198 · 2024 $1,309 · 2025 $1,857
Food & beverage: $1,857
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 43 | $728 |
| AstraZeneca Pharmaceuticals LP | 5 | $262 |
| Novo Nordisk Inc | 15 | $249 |
| PFIZER INC. | 12 | $142 |
| Lilly USA, LLC | 3 | $138 |
| GlaxoSmithKline, LLC. | 4 | $83 |
| Vanda Pharmaceuticals Inc. | 3 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $41 |
Products named: QULIPTA, VRAYLAR, AIRSUPRA, ZEPBOUND, FARXIGA, Rybelsus, TRELEGY ELLIPTA, Ozempic.
Industry payments across PA — which companies pay providers there.
